ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial
Ulrich Herrlinger(University of Tübingen), Martin Glas(Essen University Hospital), Peter Vajkoczy(Humboldt-Universität zu Berlin), Stefanie Brehmer(Montreal Neurological Institute and Hospital), Niklas Schäfer(University Hospital Bonn), Roland Goldbrunner(University of Cologne), Hartmut Vatter(University Hospital Bonn), Matthias Simon(University of Bonn), Sied Kebir(University of Bonn), Rolf Fimmers(University of Bonn), Astrid Weyerbrock(University of Freiburg), Vera C. Keil(Amsterdam Neuroscience), Oliver Schnell(Friedrich-Alexander-Universität Erlangen-Nürnberg), Michael Nelles(University Hospital Bonn), Peter Hau(University Hospital Regensburg), Lars Bullinger(Stanford University), Oliver Grauer(University Hospital Münster), Theophilos Tzaridis(Sanford Burnham Prebys Medical Discovery Institute), Friederike Schmidt‐Graf(TUM Klinikum), Uwe Schlegel(Defence Research and Development Organisation), Walter Stummer(University of Münster), Christoph Coch(University of Bonn), Elke Hattingen(Goethe University Frankfurt), Johannes Weller(University Hospital Bonn), Oliver Baehr(Goethe University Frankfurt), Joachim P. Steinbach(Goethe University Frankfurt), Rolf-Dieter Kortman(Leipzig University), Florian Ringel(Johannes Gutenberg University Mainz), Michael Sabel(Düsseldorf University Hospital), Ghazaleh Tabatabai(Goethe University Frankfurt), Frederic Mack(University of Bonn), Torsten Pietsch, Martin Uhl(Friedrich-Alexander-Universität Erlangen-Nürnberg), Dietmar Krex
Cited by 22
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial
|The Lancet Oncology|2006|3.4k
EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME
|Neurosurgery|2008|1k
Use of Gene-Expression Profiling to Identify Prognostic Subclasses in Adult Acute Myeloid Leukemia
|New England Journal of Medicine|2004|997